Update from the International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication
AIDS INFORMATION NEWSLETTER
AIDS Information Center
VA Medical Center, San Francisco
The following references are in: Program and abstracts of the
International Workshop on HIV Resistance, Treatment Strategies, and
Eradication; St. Petersburgh FL, USA June 25-28, 1997.
1. Condra JH, Holder DJ, Graham DJ, Shivaprakash M, Laird DT,
Schleif WA, Chodakewitz JA, Emini EA. Genotypic or phenotypic
susceptibility testing may not predict clinical responses to
indinavir [abstract 47].
2. Deeks S, Eastman S, Horton C, Gee C, Fischer L, Salgo M, Grant
R. Addition of saquinavir
soft gel capsule to existing
antiretroviral therapy: virological predictors of response
3. Dulioust A, Paulous S, Guillemot L, Boue F, Galanaud P, Clavel
F. Selection of saquinavir-resistant mutants following a switch
from saquinavir [abstract 16].
4. Eastman PS, Duncan IB, Gee C, Race E. Acquisition of genotypic
mutations associated with reduced susceptibility to protease
inhibitors during monotherapy [abstract 30].
5. Emini EA, Holder DJ, Schleif WA, Danovich RM, Graham DJ, Laird
DT, Shivaprakash M, Chodakewitz JA, Condra JH. Evidence for
prevention of new HIV-1 infection cycles in patients treated with
indinavir plus zidovudine plus lamivudine [abstract 128].
6. Gunthard H, Wong J, Ignacio C, Havlir D, Richman D. Emergence
of drug resistance in different tissue compartments in 10 patients
using population-based sequencing after 1 year of potent
antiretroviral therapy [abstract 66].
7. Hammer S, Demeter LM, Fischl MA, Squires KE, Bosch RJ, Hughes
MD for the ACTG 320 Study and Virology Teams. Clinical,
immunological and virological outcomes in ACTG 320, a randomized,
placebo controlled trial of indinavir in combination with two
nucleosides in HIV-1 infected persons with CD4+ cell/counts < 200
cells/mm3 [abstract 67].
8. Imanichi H, Zhang Y-M, Lane HC, Faloon J, Salzman NP. Continued
evolution of HIV-1 during combination therapy despite levels of
HIV-1 < 500 copies/ml [abstract 63].
9. Kemp SD, Bloor S for the FASP Resistance Study Group. Two
distinct mutational pathways for HIV-1 RT confer zidovudine/
lamivudine dual resistance [abstract 11].
10. Kempf D, Rode R, Xu Y, Sun E, Japour A, Danner S, Boucher C,
Leonard J, Molla A. The durability of response to protease
inhibitor therapy is predicted by viral load [abstract 62].
11. Lawrence J, Schapiro J, Pesano R, Winters M, Cain P, Winslow
D, Merigan TC. Clinical response and genotypic resistance of
sequential therapy with nelfinavir followed by indinavir plus
nevirapine in saquinavir/reverse transcriptase inhibitor-
experienced patients [abstract 64].
12. Mayers DL, Gallahan DL, Martin GJ, Emmons WW, Chung RCY,
Spooner KM, Newton JA, Aronson NE, Weislow OS. Drug resistance
genotypes from plasma virus of HIV-infected patients failing
combination drug therapy [abstract 80].
13. Molla A, Korneyeva M, Chernyavskiy T, Colgrove R, Chung PH,
Japour A, Mellors J, Xu Y, Rode R, Hsu A, Granneman GR, Kempf D,
Leonard J, Sun E and the M96-462 Study Team. Characterization of
HIV-1 protease mutations, compliance and drug concentrations in
patients who have an HIV RNA rebound on ritonavir-saquinavir
14. Montaner J, De Masi R, Dawson D, Hill A on behalf of the CEASAR
Coordinating Committee. Validation of HIV-1 RNA and CD4 count as
surrogate markers in the CEASAR trial: preliminary results
15. Natarajan V, Lane HC, OþNiell DP, Dewar RL, Metcalf JA, Vogel
S, Bechtel C, Mican J, Ward D, Rosenthal J, Kovacs JA. Detection
of HIV-1 RNA in the plasma of patients in whom HIV-1 RNA is
undetectable using commercial assays [abstract 51].
16. Patick AK, Kuritzkes D, Johnson VA, Shugarts D, Bakhtiari M,
Potts KD, Farnsworth A, Anderson R, Koel JL, Hazelwood JD, Nail CD,
Duran M, Markowitz M, Ho D, Richman D. Genotypic and phenotypic
analyses of HIV-1 variants isolated from patients treated with
nelfinavir and other HIV-1 protease inhibitors [abstract 18].
17. Quinones-Mateu ME, Albright JL, MariosJ-P, Ghosh M, Le Grice
S, Hough C, Wainberg MA, Arts EJ. A unique mechanism for
zidovudine-resistance and evidence for a zidovudine-mediated cross-
resistance to other nucleoside analogues by zidovudine-resistant
viruses [abstract 10].
18. Schinazi RF, Lloyd RM, Hough LM, Lennox JL, Hart C, Stuyver L,
Ellerbrock TV and the EVE Study Group. HIV genotyic variation in
plasma and vaginal lavages in response to antiretroviral therapy
19. Smith T, Swanstrom R. Biological cross-resistance to HIV-1
protease inhibitors [abstract 15].
20. Winters M, Schapiro J, Lawrence J, Merigan M. Genotypic and
phenotypic analysis of the protease gene in HIV-1 infected patients
that failed long-term saquinavir therapy and switched to other
protease inhibitors [abstract 17].
21. Young B, Johnson S, Bakhtiari M, Shugarts D, Young R, Allen M,
Kuritzkes D. Genotypic analysis of HIV-1 protease from patients
failing highly active anti-retroviral therapy: preliminary analysis
22. Zhang Y-M, Imamichi H, Imamichi T, Lane HC, Falloon J,
Vasudevachari MB, Salzman NP. Drug resistance during indinavir
therapy is caused by mutations in the protease gene and in its gag
substrate cleavage sites [abstract 19].
Table of Contents